With over 20 approved products and several under development, The Avastin® biosimilars market is projected to witness noteworthy growth over the coming years, claims Roots Analysis
In 2020, revenues from the sales of Avastin®, Roche’s anti-VEGFA antibody based therapeutic, were observed to have declined by 25% due to competition from biosimilars, in the United States, Europe, Japan, and other nations where it is approved
For additional details, please visit https://www.rootsanalysis.com/....reports/avastin-bios or email [email protected]
